RxDoctor Payments Data

Rony Awaida, MD

Gastroenterology · Warren, OHNPI 1306942008

Payments from drug & device makers

$17,089in general payments, 2019–2025

Across 965 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Johnson & Johnson$1K
  • Sanofi$883
  • Intercept Pharmaceuticals, Inc.$598
  • plus $5K from 33 others

What the payments were for

  • Food & beverage$16,93499%
  • Education$1561%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,089 in reported general payments places this provider in the 75th percentile of 657 gastroenterology providers in Ohio.

See all gastroenterology providers in Ohio

Medicare billing

Part B allowed, 2024
$152,013
Medicare patients
282
Services billed
1,848

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin26$85,729
Humira(Cf) PenAdalimumab12$82,414
LinzessLinaclotide29$16,649
Mesalamine46$12,341
SutabSod Sulf/Pot Chloride/Mag Sulf54$8,922
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates134$8,605
Pantoprazole Sodium525$4,035
Omeprazole261$2,472
ClenpiqSod Picosulf/Mag Ox/Citric Ac14$2,397
Sucralfate96$2,116
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl66$1,283
Ondansetron OdtOndansetron25$1,023
Famotidine98$1,021
Ondansetron Hcl28$826
Budesonide DrBudesonide14$764

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,946$85,72926 claims
AbbVieLinzess$4,675$16,64929 claims
Braintree Laboratories, Inc.Sutab$211$8,92254 claims
Ferring Pharmaceuticals Inc.Clenpiq$274$2,39714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 657 gastroenterology providers in Ohio.

Other gastroenterology in Warren

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →